Introduction
Tacrolimus (Prograf s , FK506, Fujisawa Healthcare) is a widely used immunosuppressive agent for the prevention and treatment of solid organ transplant rejection. It is also used for the prevention and treatment of graft-versus-host disease (GVHD) after allogeneic blood and marrow transplant (alloBMT). 1 Oral preparations of tacrolimus are commercially available in 0.5, 1 and 5 mg gelatin capsules. There is also an intravenous formulation available in a 5 mg/ml concentration containing dehydrated alcohol and hydrogenated castor oil as stabilizing agents. Owing to the presence and nature of these stabilizing agents in the intravenous formulation, it cannot be used to compound an oral suspension. The capsule formulation is not suitable for pediatric patients who are often unable to swallow the capsules, and/or adult patients with swallowing difficulties or patients who need other than 0.5 mg incremental dose adjustment to optimize therapeutic drug levels. Solid organ transplant dosing ranges are from 0.1 to 0.2 mg per kg of body weight per day with target therapeutic serum levels of 5-20 ng/ml, whereas alloBMT oral dosing ranges are from 0.01 to 0.09 mg per kg per day depending on renal function with target therapeutic serum levels of 5-15 ng/ml. Thus, for a 50 kg adult, the dosing could range between 0.5 and 4.5 mg daily. As tacrolimus oral dosing frequency is twice daily, capsule dosing would not be adequate for maintaining stable therapeutic levels at lower daily doses without wide fluctuations in tacrolimus levels. 2 The need for lower therapeutic serum levels for GVHD prophylaxis is a compelling reason for developing an oral suspension that allows more specific dosage adjustments. To date, there are no data comparing the bioavailability of tacrolimus suspension versus capsule. The oral absorption of the capsule is erratic and incomplete with an absolute bioavailability of approximately 25%. 2 Therefore, dosage adjustments are routinely based on serum blood levels. Incremental dosing allows better adjustment of therapy based on serum level monitoring, which may vary owing to initial interactions with other therapeutic agents patients may receive. These agents include antibacterial, antifungal and antiviral medications as well as other immunosuppressive treatment. In addition, the complexity of medication regimens can lead to medication errors. Previously, Jacobson et al. 3 demonstrated that tacrolimus can be compounded into an oral suspension of 0.5 mg/ml for use in pediatric patients. This study also demonstrated that a formulation of oral tacrolimus at a concentration of 0.5 mg/ml was stable for 56 days at room temperature. Based on these data, this 0.5 mg/ml oral formulation has been routinely used for incremental dosing in the majority of BMT patients. However, in our practice setting, we found that patients and their caregivers would mistakenly administer doses on a 1 mg/ml basis resulting in underdosing, inadequate serum drug levels and potentially adverse clinical outcomes. At our insititution, approximately five incidents per year have occurred owing to patient or caregiver error with the 0.5 mg/ml tacrolimus suspension concentration. We postulated that a 1 mg/ml oral suspension would be optimal for decreasing medication errors.
Therefore, we initiated a series of experiments to formulate an extemporaneous oral suspension of tacrolimus using commercially available drug product (Prograf s ) and excipients (inert vehicle) that included suspending agents and flavoring additives as there were no formal stability studies or clinical trials using an extemporaneous liquid formulation of Prograf s at a 1 mg/ml concentration. The objective of this study was to determine the long-term stability of a 1 mg/ml tacrolimus suspension compounded from commercially available capsules.
Materials and methods

Suspension preparation
Tacrolimus (Prograf s , Fujisawa, Deerfield, IL, USA) suspensions were prepared to a final concentration of 1 mg/ml using tacrolimus 5 mg capsules. The suspending and sweetening agents were Ora-Plus s (Paddock Laboratories, Minneapolis, MN, USA) and Ora-Sweet s (Paddock Laboratories, Minneapolis, MN, USA), respectively. OraPlus s is a suspending agent consisting of purified water, microcrystalline cellulose, carboxymethylcellulose, xanthan gum and carrageenan. Ora-Sweet s is a syrup vehicle, which contains purified water, sucrose, glycerin, sorbitol and flavoring. Each suspension was prepared by placing the contents of six tacrolimus 5 mg capsules (total 30 mg) in a 4-oz amber-colored plastic bottle and adding approximately 5 ml of sterile water. The bottle was agitated until the contents of the capsules were dispersed and a slurry formed. Equal parts of Ora-Plus s and Ora-Sweet s were added to bring the final volume to 30 ml. Triplicate, 3 ml study samples were prepared, and stored at room temperature (23-261C) in 2-oz capped plastic ambercolored bottles until assayed by high-performance liquid chromatography (HPLC). At the time of HPLC analysis, the samples were 132 and 78 days old. A fresh preparation of tacrolimus suspension was prepared on the day of HPLC analysis (day 0).
Tacrolimus extraction and high-performance liquid chromatography analysis Tacrolimus was extracted by liquid-liquid partition. All samples were extracted in duplicate. The extraction procedure consisted of adding 0.5 ml of acetonitrile (ACN) to an equal volume of tacrolimus suspension followed by vigorous mixing and centrifugation at 14 000 r.p.m. for 10 min at room temperature. The upper ACN layer was collected and analyzed for tacrolimus by reverse-phase HPLC as previously described. 4 Briefly, tacrolimus in 10 ml of the ACN layer was separated on 250 Â 4.6 mm, 5 mm C18 column (Zorbax s column, Agilent
Technologies, Palo Alto, CA, USA), maintained at 701C using H 2 O:ACN (35:65 vol/vol) as the mobile phase at a flow rate of 1.7 ml/min. The elution of tacrolimus was monitored at 214 nm wavelength. The capacity of our HPLC assay to detect tacrolimus degradation was evaluated using tacrolimus suspension subjected to pH410 achieved by adding an equal volume of 2 N NaOH, then to pHo2 using 6 N HCl and finally to neutral pH before extraction. 4 
Data analysis
The tacrolimus peak area in the freshly prepared sample was compared to the peak areas in the 78-and 132-day-old samples. The tacrolimus peak area in the fresh sample was assigned a reference value of 100%. A decrease of greater than 10% in the tacrolimus peak area was considered to demonstrate significant drug concentration deterioration.
As noted in the previous section, acid and base treatment of the tacrolimus suspension was performed as a deterioration control.
Statistical analysis
Descriptive statistics include the median and ranges for the tacrolimus concentrations. Mean concentrations were compared using a two-sided ANOVA test, with Po0.05 considered statistically significant. Figure 1 shows chromatograms of the extracts from a mixture of simple syrup and Ora-Plus s , a suspending vehicle, with no tacrolimus added (panel a) and a freshly prepared tacrolimus sample suspension (panel b). The addition of alkaline and acidic conditions caused an 80% decrease of the tacrolimus peak in the extraction chromatogram (panel c). In addition, early eluting tacrolimus degradation product peaks were detected (panel c). Chromatograms are from day 78 (panel d) and 132 (panel e) tacrolimus samples. Tacrolimus peak areas in the day 78 and 132 sample extracts were essentially the same as the day 0 sample extract (495% of the panel b chromatogram tacrolimus peak) (Figure 1 ). This is further demonstrated in Table 1 , comparing the day 0, 78 and 132 peak 1 areas that are essentially identical.
Results
Discussion
This analysis demonstrates that tacrolimus formulated as a 1 mg/ml suspension and compounded extemporaneously in equal amounts of Ora-Plus s and Ora-Sweet s is stable for at least 4 months at room temperature. We confirmed the findings of the previous publication demonstrating that a 0.5 mg/ml suspension is stable for 56 days, but at the higher concentration. A 1 mg/ml tacrolimus suspension will facilitate several aspects of clinical care. Most importantly, the 1:1 ratio of drug to suspension volume will decrease the frequency of patient medication errors, as it allows for a more simplified and straightforward drug administration. This will facilitate easier discharge medication instructions or any follow-up discharge instruction in the outpatient clinic when confirming and verifying dosing of this particular medication. Incremental dosing with the 1 mg/ ml suspension allows for more accurate adjustment of therapy based on monitoring blood levels. Pediatric dosing could result in better compliance owing to the smaller volume required for dosing (1 mg equals 1 ml instead of 2 ml at the previously manufactured 0.5 mg/ml suspension concentration). Most important is the ability to titrate tacrolimus dosing in increments less than 0.5 mg, which are the smallest available capsule size. This incremental dosing facilitates maintenance of stable therapeutic levels and will result in less fluctuation of tacrolimus levels. An unexpected finding was the long-term stability of the tacrolimus suspension (up to 4 months) as well as the difficulty in degrading the tacrolimus. Table 1 . Table 1 Comparison of peak 1 areas from Figure 1 , panels b (day 0), d (day 78) and e (day 132)
Sample
Tacrolimus peak area median (range) There were no differences in the tacrolimus peak areas (P ¼ 0.16).
Extended stability of 1 mg/ml tacrolimus suspension A Elefante et al
This study demonstrates the long-term stability of tacrolimus suspension at a 1 mg/ml concentration, and will allow for a much easier and less complicated method of tacrolimus administration for patients and their caregivers. Our suspension formulation allows smooth and accurate titration of tacrolimus to achieve desired levels. By removing any possible confusion regarding the mg and ml of dosing tacrolimus suspension with this 1 mg/ml strength, both efficacy and safety can be optimized. Since the initiation of the 1 mg/ml tacrolimus concentration in May 2004, with routine compliance monitoring, there have been no observed medication errors detected by our transplant patients or their caregivers.
